Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.35 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.32 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089749 | 0.79 | — | — | |
| SCHEMBL364870 | 0.78 | P2RX7 (0.36) | NOS3NOS2P2RX7KMONOTUM | |
| SCHEMBL6805218 | 0.77 | AAK1 (0.38) | NOS3NOS2P2RX7KMONOTUM | |
| SCHEMBL21979063 | 0.75 | P2RX7 (0.38) | NOS3NOS2P2RX7KMONOTUM | |
| SCHEMBL31097846 | 0.75 | NOS2 (0.39) | NOS3NOS2P2RX7KMONOTUM | |
| SCHEMBL6971787 | 0.75 | P2RX7 (0.34) | NOS3NOS2P2RX7KMONOTUM | |
| SCHEMBL20088854 | 0.75 | NOS2 (0.39) | NOS3NOS2P2RX7KMONOTUM | |
| SCHEMBL22056622 | 0.75 | P2RX7 (0.38) | P2RX7NOTUMPOLB | |
| SCHEMBL30901282 | 0.75 | P2RX7 (0.38) | NOS3NOS2P2RX7KMONOTUM | |
| SCHEMBL3080095 | 0.75 | P2RX7 (0.36) | P2RX7KMONOTUMSLC40A1SMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-09-16 | — | — | US | claimed |
| US-7705158-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2010-04-27 | — | — | US | claimed |
| US-8338608-B2 | Inhibitors of ion channels | ICAGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705158-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1945029-A2 | INHIBITORS OF ION CHANNELS | Icagen, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | ICAGEN (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007056099-A2 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | NOS3 1947/4885NOS2 2142/4885P2RX7 117/4885 |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | NOS3 1947/4885NOS2 2142/4885P2RX7 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.